[Pathophysiology and pharmacotherapy of benign prostatic disorders]

Nihon Yakurigaku Zasshi. 2022;157(3):164-167. doi: 10.1254/fpj.21103.
[Article in Japanese]

Abstract

Men with benign prostatic hyperplasia (BPH) often experience symptoms of overactive bladder (OAB), and bladder outlet obstruction (BOO) is one of cause of BPH. It has been suggested that bladder myogenic microcontractions or micromotions may partly contribute to the development of urgency (bladder sensory (afferent) hypersensitivity) in OAB related to BOO. We have investigated the direct effects of drugs (β3-adrenoceptor agonists, α1-adrenoceptor antagonists, PDE type5 inhibitors) on the bladder afferent function in BOO rats. In our results, almost all drugs may act on the bladder afferent function, and mirabegron inhibits the afferent activities through the suppression of the bladder myogenic microcontractions in BOO condition. Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) causes long-standing pain and/or storage symptoms including storage symptoms, such as urgency and frequency. We evaluated the likelihood of deterioration of bladder sensation in a carrageenan-induced CP/CPPS model. In results, the carrageenan-induced CP/CPPS rat model showed edema, ischemia, and inflammatory pain in the prostate, whereas a little change was detected in bladder sensation. These findings demonstrated that the bladder sensation is unlikely deteriorated in this model, suggesting CP/CPPS is possibly overlapping with symptoms in BPH.

MeSH terms

  • Animals
  • Carrageenan / therapeutic use
  • Female
  • Humans
  • Male
  • Pelvic Pain / drug therapy
  • Pelvic Pain / etiology
  • Prostatic Hyperplasia* / complications
  • Prostatic Hyperplasia* / drug therapy
  • Rats
  • Receptors, Adrenergic / therapeutic use
  • Urinary Bladder, Overactive* / drug therapy

Substances

  • Receptors, Adrenergic
  • Carrageenan